ORIC Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Oric Pharmaceuticals, Inc. (Nasdaq: ORIC) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in South San Francisco, California. The company's core mission is to improve patients' lives by "Overcoming Resistance In Cancer" (ORIC). Rather than pursuing a broad oncology portfolio, ORIC focuses on precision oncology, targeting genetically defined cancers and tumor types where resistance to existing therapies limits long-term clinical benefit. Its pipeline leverages specialized expertise in hormone-dependent cancers, precision oncology, and key tumor dependencies. The company operates an asset-light model, utilizing internal teams for research, clinical strategy, and regulatory planning, while outsourcing manufacturing and clinical trial execution to third-party contract manufacturing organizations and clinical research vendors.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Focusing operational and financial resources primarily on the clinical advancement of the two lead oncology programs, Rinzimetostat (ORIC-944) and Enozertinib (ORIC-114), while reducing preclinical research activities.
Expected impact: Extends cash runway into the second half of 2028 and optimizes resource allocation toward late-stage clinical development.
Initiating and executing the first global Phase 3 registrational trial of Rinzimetostat (ORIC-944) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Expected impact: Establishes a path toward potential regulatory approval and commercialization in a major oncology indication.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
High
Terms: Under the agreement, Bayer supplies clinical drug supply for combination studies evaluating Rinzimetostat.
High
Terms: Under the agreement, J&J supplies clinical drug supply (such as amivantamab) for combination studies evaluating Enozertinib.